Dr. G.E. Linthorst MD

Scientific staff member (UD)
Main activities
Teaching, Patient care
Medical Education
Focus of research

Medical Edcucation

Key publications
  • Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CEM, Linthorst GE, Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome. PLOS ONE 2012;7 (10):e47805-(7 p.) [PubMed]
  • Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. NEW ENGL J MED 2001;345 (1):9-16 [PubMed]
  • Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. AM J HUM GENET 2004;75 (1):65-74 [PubMed]
  • Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG, Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. KIDNEY INT 2004;66 (4):1589-1595 [PubMed]
  • Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M, Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. NAT REV ENDOCRINOL 2016;12 (10):606-615 [PubMed]
All Publications